HK1207115A1 - Microrna compounds and methods for modulating mir-21 activity mir-21 rna - Google Patents
Microrna compounds and methods for modulating mir-21 activity mir-21 rnaInfo
- Publication number
- HK1207115A1 HK1207115A1 HK15107699.2A HK15107699A HK1207115A1 HK 1207115 A1 HK1207115 A1 HK 1207115A1 HK 15107699 A HK15107699 A HK 15107699A HK 1207115 A1 HK1207115 A1 HK 1207115A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mir
- rna
- methods
- modulating
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261741783P | 2012-04-25 | 2012-04-25 | |
US201261717927P | 2012-10-24 | 2012-10-24 | |
US201361779913P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/037913 WO2013163258A1 (en) | 2012-04-25 | 2013-04-24 | Microrna compounds and methods for modulating mir-21 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207115A1 true HK1207115A1 (en) | 2016-01-22 |
Family
ID=48289681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107699.2A HK1207115A1 (en) | 2012-04-25 | 2015-08-10 | Microrna compounds and methods for modulating mir-21 activity mir-21 rna |
Country Status (29)
Country | Link |
---|---|
US (5) | US8969317B2 (xx) |
EP (1) | EP2841579B1 (xx) |
JP (1) | JP6322189B2 (xx) |
KR (4) | KR102369722B1 (xx) |
CN (1) | CN104254607B (xx) |
AR (1) | AR090825A1 (xx) |
AU (1) | AU2013251696B2 (xx) |
BR (1) | BR112014026639A8 (xx) |
CA (1) | CA2869639A1 (xx) |
CL (3) | CL2014002844A1 (xx) |
CO (1) | CO7111303A2 (xx) |
CR (1) | CR20140524A (xx) |
DO (1) | DOP2014000233A (xx) |
EA (1) | EA030211B1 (xx) |
EC (1) | ECSP14028612A (xx) |
GT (1) | GT201400221A (xx) |
HK (1) | HK1207115A1 (xx) |
IL (1) | IL234904B (xx) |
IN (1) | IN2014DN09134A (xx) |
MX (1) | MX353562B (xx) |
MY (1) | MY173600A (xx) |
NZ (1) | NZ630591A (xx) |
PE (1) | PE20142404A1 (xx) |
PH (1) | PH12014502387A1 (xx) |
SG (1) | SG11201406931XA (xx) |
TW (1) | TWI647235B (xx) |
UA (1) | UA117098C2 (xx) |
WO (1) | WO2013163258A1 (xx) |
ZA (1) | ZA201407228B (xx) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
SI2702155T1 (sl) | 2011-04-25 | 2017-07-31 | Regulas Therapeutics Inc. | Spojine MicroRNA in postopki za modulacijo aktivnosti MIR-21 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
SG10201604896TA (en) | 2011-12-16 | 2016-08-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
JP2015513913A (ja) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ポリヌクレオチド |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013153082A1 (en) * | 2012-04-10 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of nonalcoholic steatohepatitis |
AU2013251696B2 (en) | 2012-04-25 | 2018-11-15 | Sanofi | MicroRNA compounds and methods for modulating miR-21 activity |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
EP4086347A3 (en) * | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9994846B2 (en) | 2013-10-25 | 2018-06-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
US20160289678A1 (en) * | 2013-11-22 | 2016-10-06 | Dcb-Usa Llc | Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microrna 146-a antagonists |
WO2015123449A2 (en) * | 2014-02-12 | 2015-08-20 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
WO2015154002A1 (en) * | 2014-04-04 | 2015-10-08 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
CN105087477A (zh) * | 2015-05-21 | 2015-11-25 | 王松灵 | miR-21反义核苷酸修饰的骨髓间充质干细胞的用途 |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
KR20190141770A (ko) * | 2017-05-04 | 2019-12-24 | 사노피 | 알포트 증후군의 치료 방법 |
WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
AU2019381681A1 (en) * | 2018-11-13 | 2021-05-27 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating miR-10b activity |
WO2021020412A1 (ja) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Murf1を標的とする核酸医薬 |
KR102293777B1 (ko) * | 2019-12-31 | 2021-08-25 | 연세대학교 산학협력단 | 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법 |
BR112022017215A2 (pt) * | 2020-04-09 | 2022-10-18 | Univ Muenchen Tech | Liberação direcionada de um inibidor de mir-21 aos macrófagos para o tratamento de fibrose pulmonar |
US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
KR102328770B1 (ko) * | 2020-06-01 | 2021-11-19 | 고려대학교 산학협력단 | 비알코올 지방간염 진단용 바이오마커 miRNA-4449 |
KR102360963B1 (ko) * | 2020-07-28 | 2022-02-09 | 고려대학교 산학협력단 | microRNA조합을 이용한 비알코올 지방간염 진단용 바이오마커 |
WO2022072336A1 (en) * | 2020-10-01 | 2022-04-07 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9911067A (pt) | 1998-05-22 | 2001-02-06 | Boys Town Nat Res Hospital | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal |
US20060008817A1 (en) | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
ES2382807T3 (es) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación |
EP2290070B1 (en) | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
WO2006020768A2 (en) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
EP1802331A2 (en) | 2004-09-08 | 2007-07-04 | Boys Town National Research Hospital | Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12 |
EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
EP1931780B1 (en) * | 2005-08-29 | 2016-01-06 | Regulus Therapeutics Inc. | Antisense compounds having enhanced anti-microrna activity |
EP2388327A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
SG170773A1 (en) | 2006-04-03 | 2011-05-30 | Santaris Pharma As | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EA015570B1 (ru) | 2006-04-03 | 2011-10-31 | Сантарис Фарма А/С | Фармацевтическая композиция |
ES2611924T3 (es) | 2006-10-03 | 2017-05-11 | Arbutus Biopharma Corporation | Formulaciones que contienen lípidos |
WO2008043521A2 (de) | 2006-10-09 | 2008-04-17 | Julius-Maximilians-Universität Würzburg | Microrna (mirna) zur diagnose und therapie von herzerkrankungen |
CA2671294A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
US20100261175A1 (en) | 2007-06-15 | 2010-10-14 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
EP2623599B1 (en) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
US20110257244A1 (en) | 2008-01-18 | 2011-10-20 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2010099161A1 (en) * | 2009-02-26 | 2010-09-02 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
MX2011013176A (es) | 2009-06-08 | 2012-04-30 | Miragen Therapeutics | Motivos de modificación química para inhibidores y miméticos del miarn. |
WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
SI2702155T1 (sl) | 2011-04-25 | 2017-07-31 | Regulas Therapeutics Inc. | Spojine MicroRNA in postopki za modulacijo aktivnosti MIR-21 |
WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
AU2013251696B2 (en) | 2012-04-25 | 2018-11-15 | Sanofi | MicroRNA compounds and methods for modulating miR-21 activity |
EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
EP2900822B1 (en) | 2012-09-26 | 2021-11-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligomers with improved off-target profile |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2013
- 2013-04-24 AU AU2013251696A patent/AU2013251696B2/en active Active
- 2013-04-24 KR KR1020207015330A patent/KR102369722B1/ko active IP Right Grant
- 2013-04-24 MX MX2014012476A patent/MX353562B/es active IP Right Grant
- 2013-04-24 UA UAA201412637A patent/UA117098C2/uk unknown
- 2013-04-24 JP JP2015509097A patent/JP6322189B2/ja active Active
- 2013-04-24 KR KR1020147032508A patent/KR102118429B1/ko active IP Right Grant
- 2013-04-24 WO PCT/US2013/037913 patent/WO2013163258A1/en active Application Filing
- 2013-04-24 BR BR112014026639A patent/BR112014026639A8/pt not_active Application Discontinuation
- 2013-04-24 NZ NZ630591A patent/NZ630591A/en unknown
- 2013-04-24 KR KR1020237008046A patent/KR20230037703A/ko not_active Application Discontinuation
- 2013-04-24 US US13/869,177 patent/US8969317B2/en active Active
- 2013-04-24 KR KR1020227006324A patent/KR20220028183A/ko active Application Filing
- 2013-04-24 MY MYPI2014003019A patent/MY173600A/en unknown
- 2013-04-24 IN IN9134DEN2014 patent/IN2014DN09134A/en unknown
- 2013-04-24 EP EP13720699.1A patent/EP2841579B1/en active Active
- 2013-04-24 SG SG11201406931XA patent/SG11201406931XA/en unknown
- 2013-04-24 PE PE2014001895A patent/PE20142404A1/es not_active Application Discontinuation
- 2013-04-24 CA CA2869639A patent/CA2869639A1/en not_active Abandoned
- 2013-04-24 EA EA201491953A patent/EA030211B1/ru not_active IP Right Cessation
- 2013-04-24 TW TW102114690A patent/TWI647235B/zh active
- 2013-04-24 CN CN201380020336.8A patent/CN104254607B/zh active Active
- 2013-04-24 AR ARP130101370A patent/AR090825A1/es active IP Right Grant
-
2014
- 2014-07-29 IL IL23490414A patent/IL234904B/en active IP Right Grant
- 2014-10-06 ZA ZA2014/07228A patent/ZA201407228B/en unknown
- 2014-10-16 DO DO2014000233A patent/DOP2014000233A/es unknown
- 2014-10-17 GT GT201400221A patent/GT201400221A/es unknown
- 2014-10-22 CL CL2014002844A patent/CL2014002844A1/es unknown
- 2014-10-24 PH PH12014502387A patent/PH12014502387A1/en unknown
- 2014-10-28 CO CO14238778A patent/CO7111303A2/es unknown
- 2014-11-14 CR CR20140524A patent/CR20140524A/es unknown
- 2014-11-25 EC ECIEPI201428612A patent/ECSP14028612A/es unknown
-
2015
- 2015-01-15 US US14/597,676 patent/US9267137B2/en active Active
- 2015-08-10 HK HK15107699.2A patent/HK1207115A1/xx unknown
-
2016
- 2016-01-14 US US14/995,432 patent/US9688985B2/en active Active
-
2017
- 2017-02-24 US US15/441,590 patent/US9970009B2/en active Active
- 2017-05-11 CL CL2017001195A patent/CL2017001195A1/es unknown
-
2018
- 2018-04-16 US US15/954,159 patent/US20180305691A1/en not_active Abandoned
-
2019
- 2019-07-05 CL CL2019001878A patent/CL2019001878A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273381A (en) | MicroRNA compounds and methods to modulate mir-21 activity | |
HK1207115A1 (en) | Microrna compounds and methods for modulating mir-21 activity mir-21 rna | |
HK1217477A1 (zh) | 位點特異性核酸酶活性的 檢測方法 | |
HK1221256A1 (zh) | 用於調節 的微小 化合物和方法 | |
DK2922554T3 (en) | Terminalt modificeret rna | |
EP2850184A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION | |
EP2850183A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION | |
EP2799548A4 (en) | ANTISENSE NUCLEIC ACID | |
SG11201405542UA (en) | Artificial nucleic acid molecules | |
EP2839016A4 (en) | CELL TRANSFECTION METHOD | |
EP2850189A4 (en) | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION | |
HK1201878A1 (en) | Oligonucleotides for modulating gene expression and uses thereof | |
EP2915815A4 (en) | NEW MODIFIED NUCLEIC ACID | |
EP2864469A4 (en) | BIOREACTOR CARTRIDGE AND SYSTEM | |
IL228700A0 (en) | A method for modulating cytokine activity | |
IL236116A0 (en) | Methods for controlled gene expression | |
EP2913399A4 (en) | METHOD OF PREPARING RNA | |
AU2012902347A0 (en) | Inhibition of small RNA activity |